Published in Japan, 29 July 2022

MonoSpin

Solid Phase Extraction Spin Column

MonoSpin
MonoSpin is a solid-phase extraction spin column that uses
silica monoliths with uniform continuum pores. It effectively
and rapidly extracts, isolates, purifies, and concentrates
samples by centrifugation.

【Features】• Easy operation by centrifuge• Speedy sample treatment with a superb through the pore
• Excellent reproducibility (S-type) even at 100 μL or fewer
elution volumes.

Sillica monolith

MonoSpin

Operation method
Short time centrifugation is used to pass the liquid in solid-phase extraction.
The whole sample treatment process can be done within 10 min.

Centrifuge

Conditioning

Centrifuge

Adsorption

Centrifuge

Wash

Centrifuge

ElutionCentrifuge Operation

Shape
MonoSpin series cartridges of different types are available:
Type S: Excellent for pretreating the sample for 50–800 uL
Type L: Appropriate for sample 0.5–8 mL.
For the details of the varied functional group, please see the next page.

S TypeL Type● Disk size ： 4.2 × 1.5 mm● Disk size ： 9 × 3 mm

● Sample volume ： up to 800 µL● Sample volume ： up to 8 mL

● Elution volume ： 50 to 800 μL● Elution volume ： 0.5 to 8 mL

● Centrifugation speed ： 2,000 to 10,000 ×g● Centrifugation speed ：1,000 ×g
NOTE) MonoSpin ProA and MonoSpin ProG havedifferent shapes. Please see page 16 for details.

96 Well plate type
● Sample volume ：up to 800 μL● Elution volume ： 50 to 800 μL● Centrifugation speed ：1,000 to 5,000 ×g (can be used in vacuum aspiration)
NOTE) MonoSpin C18 FF, MonoSpin ProA and MonoSpin ProG have different specifications.
Please see page 14 and 15 for details.

2Silica monolith~ New separation media that are neither particulate nor membrane ~Silica monoliths are integral silica gels with uniform continuous pores and produced from ethyl silicate. Unlike theparticle media, the silica monolith is shaped like a disk. Silica monoliths have high liquid permeability and large
surface area as they have through-pores and mesopores on their framework surface. Thus, this state-of-the-art
medium is becoming popular worldwide for its properties: high recovery, high performance of adsorption, anddesorption.

Continuous pore(through pore)

Mesopores on theframework surface
Silica monolith structure

Advantages of Monolithic SPE materials over particle packed SPE materials❖ Disk-shaped silica monoliths do not use frits to hold particle media in traditional solid-phase extraction cartridges.
❖ Monolithic material has a massive surface area, making it possible to reduce the sample volume. Silica monoliths
makes it possible to retain samples in the cartridge and completely elute small samples during processing.
❖ Despite its high liquid permeability, it is also suitable for fast elution without losing its high recovery as it achieves
rapid sample diffusion and separation.

Silica monolith

Particle-filled Form

• No filter required• Need for filters• Minimized→ liquid may beseparation media

remained in the filter

Bed volume for separation media : small

Bed volume for separation media : large

Sample diffusion in the column : fast

Sample diffusion in the column : slow

Separation speed : fast

Separation speed : slow

3

MonoSpin series lineup
MonoSpin C18/C18 FF

S

L

96

S

MonoSpin Ph

The phenyl group is chemically bonded,
which makes it feasible to use weakerhydrophobicity than C18. Therefore, it issuitable for the recovery of hydrophobic
drugs from biological samples underreversed phase mode.

Octadecyl functional group.
Optimal for drug extraction in biologicalsamples and desalting and enrichment of
peptide samples.
High-flow (FF) designs are also available.

MonoSpin C18-AX

S

96

MonoSpin C18-CX

It is a mix mode type in which both
octadecyl and quaternary ammonium
groups are chemically bonded. It canreliably retain bio-samples at high salt
concentrations and is particularly
suitable for the recovery of acidic drugs.

MonoSpin SAX

S

L

S

-

Bond with Trimethyl aminopropyl,
combining strong anion exchange andweak hydrophobic interaction. It is bestfor extracting acidic drugs.

MonoSpin NH2

S

L

96

S

MonoSpin CBA

It is bonded with an amide group. MonoSpin
amide is best for extracting sugar chains andvarious acidic and basic hydrophiliccompounds by HILIC mode.

MonoSpin TiO

It is characterized by a monolith skeleton
coated with dioxide titanium. It is excellent
for enriching phosphopeptides.

TiO2

MonoSpin ME

S

It is bonded with iminodiacetic acidgroups. Therefore, it is optimal for therecovery of trace metals in samples.

MonoSpin ProA

ProteinA

S

L

96

・・・ See page 16

96

S

96

S

ZrO2

MonoSpin ProG

L ： L-type column productsS・・・ see the page 13

L

It has a phospholipid removal column
coated with titanium dioxide and zirconium
dioxide on a silica monolith. It adsorbed
phospholipids in samples with an easy
pretreatment.

TiO2

It contains protein A, which isimmobilized on the monolith. Therefore,
it enables the efficient purification of
antibodies.

S ： S-type column products

4L

The columns are immobilized withtrypsin, a digestive protein enzyme.
It enables the rapid digestion ofproteins.

MonoSpin Phospholipid

LS

It is bonded with phenyl boric acid, which
gives you higher selectivity. Hence,
MonoSpin PBA is excellent for extracting
cis diol compounds, such as catechol
amines.

MonoSpin Trypsin

S96

It is bonded with propyl benzene sulfonicacid, combining strong cation exchange
and hydrophobic interaction. It is excellent
for extracting basic drugs.

MonoSpin PBA

96

L

It is bonded with propyl benzene sulfonicacid, combining strong cation exchange
and hydrophobic interaction. Therefore,
MonoSpin SCX is excellent for extracting
basic drugs.

It is bonded with aminopropyl and isbeneficial for enriching the sugar chain orhydrophilic compounds by HILIC mode.

MonoSpin Amide

Its octadecyl and benzenesulfonic acid groups
are bonded. Thus, purifying dissociated basic
drugs in serum and urine is appropriate.
Compared with MonoSpin C18 and SCX alone,
SCX has higher cleanup efficacy as it works ashydrophobic and ion-exchange interactions.

S

MonoSpin SCX

96

96

ProteinG

S

L

96

・・・ see the page 16

The protein G is immobilized on themonolith. Therefore, it enables theefficient purification of antibodies.

96 ： 96-well plate-type productCharacteristics of MonoSpin Series
Purification and Enrichment of Trace Analytes
Due to its high permeability, the MonoSpin series enables quicker and more efficient purification and enrichment withcentrifugation.
It is also recommended to elution small volume samples, and trace analytes can be collected without dilution.

Purification of Catecholamine by MonoSpin PBA
Sample volume : 500 µL

S typeBefore purification

Conditions

Elution Volume : 500 µL：Inertsil ODS-3 （5 µm, 150×2.1 mm I.D.）：50 mM Phosphate buffer (pH 5.6)50 mg/L EDTA, 600 mg/L IPCC-008, -10% Methanol：0.3 mL/min

ColumnEluentFlow Rate

Elution Volume : 50 µL(10-fold enrichment)

Col.Temp.
：35 ℃
Injection Vol.
：5 µL
Detection：ECD Pulse Mode
Please see page 10 for preprocessing methods, etc.

L typePurification of Serum samples by MonoSpin L C18
Sample volume : 5,000 μL
Elution volume : 500 μL(10-fold concentration)

0.00

0.00

0.10

0.10

0.20

0.20

Before purification

0

2

4

6

8

10

0

2

Conditions
ColumnEluentFlow Rate：Inertsil ODS-3 （5 µm, 150×4.6 mm I.D.）：CH3CN/3 mM KH2PO4, 27 mM SDS= 48 / 52
：1.0 mL/min

4

6

8

10

Time (min)Time (min)Col.Temp.
：40 ℃
Injection Vol. ：1 µL
Detection：230 nm5

Physical properties of MonoSpin series
Product nameMonoSpin C18

S Type / 96 well
L TypeSurface Area
Bed Capacity
Through pore Mesopore Through pore Mesopore(m2/g)(For type S)
(µm)
(nm)
(µm)
(nm)
5
10
10
10
350
100 μg Amitriptyline

Functional Group
Octadecyl group

MonoSpin C18 FF Octadecyl group

20

15

10

10

300

50 μg Amitriptyline

MonoSpin Ph

Phenyl group
Octadecyl group,
MonoSpin C18-AX
Quaternary ammonium
Octadecyl group,
MonoSpin C18-CX
Benzenesulfonic acid group

5

10

-

-

350

100 μg Amitriptyline

5

10

-

-

350

100 μg Ibuprofen

5

10

-

-

350

100 μg Amitriptyline

MonoSpin SAX

Trimethylaminopropyl group

5

10

10

10

350

100 μg Ibuprofen

MonoSpin SCX

Propylbenzenesulfonic acid group

5

10

10

10

350

100 μg Amitriptyline

MonoSpin NH2

Aminopropyl-group

5

10

10

10

350

100 μg Maltopentaose

MonoSpin CBACarboxyl group

5

10

10

10

350

100 μg Amitriptyline

MonoSpin Amide

Amide group

5

10

-

-

350

100 μg Angiotensin Ⅱ

MonoSpin PBA

Phenylboronic acids

5

10

-

-

350

100 μg Dopamine

MonoSpin TiO

Titanium dioxide

20

15

-

-

200

40 μg

MonoSpin Trypsin Trypsin

5

10

-

-

100

-

MonoSpin ME

Iminodiacetic acid group

5

10

10

10

350

25 μg Cu ions

MonoSpin
Phospholipid
MonoSpin ProA

Titanium dioxide
Zicronium dioxide
Protein A

5

10

10

10

350

10 μL Human serum

2

60

2

60

-

400 μg Human IgG

MonoSpin ProG

Protein G

2

60

2

60

-

300 μg Human IgG

Adenosinemonophosphate-

Specifications for Shape and TypeType

MonoSpin S type＊1

MonoSpin FF＊2

MonoSpin L type

MonoSpin 96 well type

Disk size

4.2×1.5 mm

4.2×1.5 mm

9×3 mm

4.2×1.5 mm

Sample Volume

Up to 800 μL

Up to 800 μL

Up to 8 mL

Up to 800 μL

Elution Volume

50 to 800 μL

50 to 800 μL

0.5 to 8 mL

100 to 800 μL

Centrifugal force

2,000 to 10,000 × g

1,000 × g

1,000 × g

1,000 to 5,000 ×g* 1:MoSpin ProA and MonoSpin ProG are different in specifications. Please refer to page 15 for the details.
* 2:FF type is available for MonoSpin C18 FF only.

The Viscosity of the Sample
The MonoSpin series is optimized as a spin column for pretreatment of biological samples. If you are working on very
viscous samples such as blood, MonoSpin C18 FF is the best choice.
Please refer to the following chart for choosing the suitable MonoSpin.
Viscosity of the sample

Low
Ex. Urine

MonoSpin C18 (Type S/ 96 well)
MonoSpin C18 FF
MonoSpin C18 (Type L)

6Viscosity
Ex. Serum Sample

High
Ex. BloodApplication
Purification of Amphetamines in urine using MonoSpin C18
Sample Volume 800 µL
Urine : 400 µL
Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 30 sec

1 min

1 min

1 min

Buffer solution (pH 13) : 400 µL*Sample was mixed for 1 min at
10,000 x g. Transferred and1. Conditioning

used the supernatant as sample.

① Methanol 300 µL② Buffer (pH 13) 300 μL(①→Centrifuge→②)

Centrifuge : 5,000×g

22. Adsorption
Sample solution
800 μＬ

4. Elution
Purified sample
3. WashBuffer (pH 13) Methanol-0.1 % Formic acid
300 μL(1:1, v/v) 100 μL

Conditions

3
5

7

Column：InertSustainSwift C18 (3 μm, 150 × 2.1 mm I.D.)

Eluent：A)10 mM HCOONH4(pH 3.3)
B) CH3OH

4

A/B = 90/10 - 2 min - 90/10 - 13 min - 70/30, v/v

6

1

Flow Rate：0.3 mL/min

Col. Temp.

：40 ℃

Detection：LC/MS

Sample： 1. Norephedrine

5. Methamphetamine

2. Ephedrine

6. 3,4-methylenedioxyamphetamine

3. Methylephedrine

7. 3,4-methylenedioxymethamphetamine※ Data provided by Dr. Namera, Hiroshima University

4. Amphetamine

Recovery of drugs in biological samples using MonoSpin C18
Sample Volume 600 µL
Serum : 200 µL
10 mM potassium phosphate :400 µL (pH 7.0)

Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 30 sec

2 min

1 min

1 min

* Sample was mixed for 1 min at
10,000 ×g. Transferred and used

1. Conditioning

2. Adsorption

Sample solution 600 μL① Methanol 300 µL②10 mM Potassium
phosphate (pH 7.0) 300 μL(①→Centrifuge→②)

the supernatant as sample.
Centrifuge : 2,300 ×g

3. Wash

4. Elution

Water 300 μL

Acetonitrile 200 μL

Purified sample

Day-to-day reproducibility of the drug in serum using MonoSpin C18 (3 days, n = 10).
SampleDesipramine

Imipramine

Fluvoxamine

5

Recovery
rate
(%)
91.2

4.8

5

Recovery
rate
(%)
83.7

3.9

5

Recovery
rate
(%)
83.7

10

86.1

3.3

10

84.1

7.8

10

81.8

2.8

50

85.2

5.9

50

83.9

8.2

50

83.8

3.0

250

88.4

6.5

250

86.7

7.5

250

88.4

2.7

5

96.3

9.5

5

97.9

9.0

10

95.8

1.5

10

95.5

8.5

50

94.5

0.9

50

90.8

2.6

250

95.9

250

92.6

3.0

5

Concentration(ng/mL)

RSD(%)

SampleParoxetine

Concentration(ng/mL)

RSD
(%)

5

85.7

8.1

10

84.7

3.2

50

88.6

5.4

0.9

250

87.5

7.7

96.8

11.6

5

106.3

9.9

10

87.1

5.0

10

104.8

6.7

50

86.8

8.1

50

99.8

8.7

250

87.5

9.7

250

99.8

6.0

Maprotiline

Duloxetine

SampleAmitriptyline

Sulpiride

Concentration(ng/mL)

RSD
(%)
7.0

7

Application
Desalination of protein digestion using MonoSpin C18
Maximum sample solution 800 μL

After Tryptic digestion,
add TFA to adjust theconcentration to o.1%.
Centrifuge : 2,300 ×g

Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 1 min

2 min

1 min

2 min

1. Conditioning

2. Adsorption

3. Wash① Acetonitrile 200 µL② 0.1% aqueous TFA 200 µL(①→Centrifuge→②)

Sample solution
Maximum 800 μＬ

0.1 % aqueous TFA
200 μL

Beforepurification

After
purification

Denaturant,salt

4. Elution

Desalted samples

60 % acetonitrile
200 μL

Conditions
Column：Inertsil ODS-3

Eluent：A)H2O (0.1 % TFA)

(3 μm, 150× 2.1 mm I.D.)

B)CH3CN (0.1 % TFA)
A/B = 90/10 - 20 min - 50/50

Enlarged view

Enlarged view

Flow Rate：0.2 mL/min

Col. Temp. ：40 ℃
Detection: UV 210 nm

Sample：Digested BSA 2 µL

Highly concentrated denaturant and salt indigestive were successfully removed using
MonoSpin C18.

Rapid Digestion of BSAs by MonoSpin's Trypsin HP■ Ex. Reductive alkylation protocol

Conditions

1 mg bovine serum-albumin----- 500 mM Tris-HCL(pH 8. 0)-- 8M urea (Solution 1): 175μL----- 40 mg/mL Dithiothreitol in Solution 1: 25μL

Column：Inertsil ODS-3

Eluent：A)H2O (0.1 %HCOOH)(3 μm, 150× 2.1 mm I.D.)

B)CH3CN (0.1 %HCOOH)----- Incubation at 37 ℃ for 90 min

A/B = 90/10 - 20 min - 50/50----- 40 mg/mL Iodoacetamide in Solution 1: 50μL

Flow Rate：0.2 mL/min----- Incubation at 37 ℃ for 30 min (under shaded conditions)Col. Temp.

：40 ℃

Detection：UV 210 nm

Sample：Digested BSA 2 µL

Reductive alkylation of proteins: 250μL----- Dilute with 50mM Ammonium bicarbonate to adjust
the urea to 2M: 750μL

MonoSpin Trypsin HP

NOTE) The method of reductive alkylation should be optimized depending on the type of protein.

● In-Solution digestion (37℃ for 10 h)● Digested with MonoSpin Trypsin HP(at 25℃ for 10 min)Trypsin-immobilized spincolumn can complete theprocess just in 10 min.

NOTE) For digestion, be sure to use protein after reductive alkylation.

8

Application
Fractionation of Protein digests using MonoSpin SCX

0.1 % HCOOH(Sample Apply)

The use of spin columns and elution salt concentration stepwise
makes it feasible to fractionate peptides without using 2D-LC or othercomplex systems.
Sample Volume: 500 µL

Used Peptide
sample dissolved in
0.1% Formic acidafter desalting with
MonoSpin C18.
Centrifuge: 10,000 ×g

Centrifuge

Centrifuge

30 sec1 min
30 sec

1. Conditioning

2. Adsorption

0.1 % formic acid
300 μL

Peptide sample
500 μL

3. Elution

Elution Fraction

Apply the eluent, centrifuge, and then attach a new tube to apply thenext eluent.
Each eluate composition①25 mM HCOONH4 200 µL④500 mM HCOONH4 200 µL②50 mM HCOONH4 200 µL⑤1 M HCOONH4③100 mM HCOONH4 200 µL

Injection) Each solution contains 10% acetonitrile.

200 µL

Conditions
Column ：Inertsil ODS-3 (3 μm, 2.1 ×150 mm)
EluentDetection：UV 210 nm：A)H2O (0.1 % HCOOH)

Flow Rate：0.2 mL/min

B)CH3CN (0.1 % HCOOH)

Col. Temp.

：40 ℃

A/B = 90/10 - 20 min - 50/50

Injection Vol. ：2 µL

Purification of pyridylaminated glycans using MonoSpin's NH2
Sample volume: 800 µL

Dissolve the sample toadjust the concentrationof ACN to 90~95%.
Centrifuge : 2,300×g

Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 1 min

1 min

1 min

1 min

1. Conditioning① 50 % acetonitrile(0.1 % formic acid) 500 μL② 90 % acetonitrile(0.1 % formic acid) 500 μL(①→Centrifuge→②)2. Adsorption
Sample solution
800 μL3. Wash90 % acetonitrile(0.1 % formic acid)
500 μL

4. Elution
50 % acetonitrile(0.1 % formic acid)50 - 800 μL

Purified sample

Conditions

Before purification

Purified with MonoSpin NH2Column：NH2 Column (5 μm, 250 × 4.6 mm I.D.)

Eluent：A)H2O/CH3CN＝5/95 0.1 % HCOOHB) H2O/CH3CN＝95/5 0.1 % HCOOH
A/B = 90/10-10 min–90/10-40 min-60/40

Flow Rate：1 mL/min

Detection：FL Em 320 nm, Ex 400 nm

Injection Vol. ：1.5 µL

9Application
Purification of Paraquat and Diquat using MonoSpin CBA
Sample volume 600 µL
Urine: 200 µL
10 mM potassium phosphate
Buffer solution (pH 7.0): 400μL
Centrifuge : 10,000 ×g

Centrifuge

Centrifuge

Centrifuge

Centrifuge

30 sec30 sec30 sec×2

30 sec

1. Conditioning

2. Adsorption

3. Wash

4. Elution

10 mM Potassium Phosphate
Buffer (pH 7. 0) 200 µL

Sample solution
600 μL

10 mM potassium phosphate
Buffer (pH 7. 0) 200 µL

1 % Hydrochloric acid
30% Methanol
69% Water
200 μL

Urine ＋ pesticide (1µg/mL each)Standard Solution (1µg/mL )Purified sample

After purification with MonoSpin CBA
Conditions
ColumnEluentParaquat:Inertsil ODS-3 (5 μm,
150 mm× 4.6 mm I.D.):0.2 M phosphoric acid,
0.1 M diethyl amine,
7.5 mM IPCC08(IPCC-0.8,
Sodium 1-Octanesulfonate)/Acetonitrile=89/11
Flow Rate:1 mL/min
Col.Temp.
:40 ℃
Detection:PDA 290 nm
Injection Vol. :50 µL

DiquatEthyl Paraquat

Recovery of hormones in serum using MonoSpin C18
Sample preparation
Add 10 μL of 1 mg/mL
adrenomedullin to serum: 190 μL.
Centrifuge the sample after additionof 0.1% TFA solution 200 μL.
Used the supernatant as sample.

Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 30 sec

1 min

1 min

1 min

1. Conditioning

2. Adsorption

3. WashSamples were prepared① Acetonitrile 200 μL② 0.1% aqueous TFA: 200μL 400 μL of supernatant(①→Centrifuge→②)

Centrifuge : 2,300 ×g

Adrenomedullin

4. Elution

Purified sample

0.1% aqueous TFA
Contain 0.1% TFA
200 µL 60% acetonitrile solution
200 μL

Conditions
Column:InertSustain C18(2 μm, 50 ×2.1 mm I.D.)
Eluent:A)0.1 % TFA in Water
B) 0.1 % TFA in Acetonitrile
A/B = 85/15 – 5 min – 50/50-2 min-50/50
Flow Rate:200 μL/min
Col. Temp.
:40 ℃
Detection:UV 210 nm
Injection Vol. :10μL
0

10

2

4
Time (min)6

Application
Purification of Catecholamines using MonoSpin PBA
Sample solution 250 µL
Sample solution(urine or serum)
200 μL1 M Dipotassium hydrogen phosphate(adjusted to pH 8 with phosphoric acid)
50μL
Centrifuge : 10,000×g

Before Purification

Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 1 min

1 min

1 min

1 min

1. Conditioning
1% acetic acid solution: 200 μL→ 100 mM Dipotassiumhydrogen phosphate
Adjusted to pH 8: 50μL

2. Adsorption
Sample solution
250 μL3. Wash100 mM hydrogen
phosphate
Aqueous dipotassium
solution(adjusted to pH 8 withphosphate) 200 µL

Purification with MonoSpin PBA (sample amount:500 µL)
Elution 50 µL

4. Elution
1% acetic acid solution
200 μL

Purified sample

Conditions

Elution 500 µL

Column:Inertsil ODS-3(5 μm, 150 mm×2.1 mm I.D.)
Eluent:50 mM Phosphate
Buffer (pH 5.6)50 mg/L EDTA
600 mg/L IPCC-008-10 % Methanol
Flow Rate :0.3 mL/min
Col.Temp. :35 ℃
Injection :5 µL
Detection :ECD Pulse Mode
Sample:1. Noradrenaline
2. Adrenaline
3. DHBA
4. Dopamine

By using MonoSpin PBA, we can selectively recover and purify compounds with cis-type diols such as catecholamines.
See our website Technical Note LT093 for more information.

Purification of Organophosphorus pesticides in human serum using MonoSpin TiO
Sample Volume 50 µL

Sample 10 µL
Water 40 µL

Centrifuge: 5,200×g

Before purification

Centrifuge

Centrifuge

Centrifuge

Centrifuge

Each 1 min

Each 1 min

Each 1 min

1 min

3. Wash

1. Conditioning

2. Adsorption① 80% acetonitrile(0.1 % TFA) 50 µL② 50% acetonitrile(0.1 % TFA) 50 µL(①→Centrifuge→②)

Sample solution 50 μL→ Collect the solution
and repeat
Put on a column

After purification using
MonoSpin TiO

4. Elution

2% ammonia solution①80% acetonitrile(0.1 % TFA) 50 µL
50 μL②50% acetonitrile(0.1 % TFA) 50 µL(①→Centrifuge→②)

Purified sample

N-acetyl-O-methyl
Derivatives
To LC/MS

Conditions
Column：ODS Column (150 ×2.1 mm I.D.)

Eluent：A)CH3OH
B)20 mM HCOONH4 (pH 3.0)
A/B = 15/85, v/v

Flow Rate：0.2 mL/min

Detection：SIM

Injection Vol. ：5 µL
Sample：1. Bialaphos
2. Glyphosate
3. MPPA
4. Glufosinate

MonoSpin TiO shows selectivity for phosphate sites in compounds.

5. AMPA11

Application
With Insulin or BSAs
Sample Preparation
Adjust concentration of Insulin
and BSA with 0.1% aqueous TFA.

Centrifuge

Centrifuge

Centrifuge

centrifuge

Each 1 min

1 min

1 min

1 min

Centrifuge : 2000×g
1. Conditioning

2. Adsorption

3. Wash4.Elution① ACN: 300μL② 0.2％ TFA in H2O: 300μL(①→Centrifuge→②)

Sample solution
300 µL

0.2 % TFA in H2O
300 µLC2H5OH/H2O/TFA=60:40:0.1 300 µL

Insulin loading volume

BSA loading volume

Overload

Max. Loading Capacity 4 mg/mL 300 μL（Sample volume ：1.2 mg）
Recovery rate : 90 %Overload

Area

Area

Purified sample

Max. Loading Capacity 0.1 mg/mL(Sample volume : 0.03 mg)
Recovery rate 86 %Please see Technical Note LT157
for more information .
Concentration(mg/mL)

Concentration(mg/mL)

Analysis of blood samples using MonoSpin C18FF
Sample Preparation
Mix blood sample(0.3mL) and 300mM
phosphate buffer(pH 10.0).
Use supernatant as sample after
centrifugation at 12,000 x g for 5 min.

2000000

a-PPP(m/z 204)

Centrifuge

Centrifuge

1 min

1 min

1 min

1 min

2.Adsorption

1. Conditioning

3. Wash

4. Elition

300 mM phosphatebuffer(pH 10): 300μL

MeOH 100 µL

Purified sample

a-PBP(m/z 218)a-PVP(m/z 232)

1500000

Centrifuge① MeOH: 300μL② 300 mM phosphate buffer(pH 10): 300μL(①→Centrifuge→②): 1,000 x g

Centrifuge

Centrifuge

a-PHP(m/z 246)

1000000

a-PHPP(m/z 260)a-POP(m/z 274)

500000

0
5

10

15

20

Conditions

12

Column: InertSustain Phenyl (3 μm, 150 ×2.1 mm I.D.)

Flow Rate: 0.2 mL/min

Eluent: CH3CN-HCOONH4(10 mM, 0.1 % HCOOH) = 25:75 (v/v)

Col. Temp.

: 40 ℃

Detection: MS(ESI)

25

min

MonoSpin Phospholipid
Phospholipid removal column coated with titanium dioxide and zirconium dioxide on
silica monolith. It adsorbs phospholipids in samples such as blood and serum witheasy pretreatment. More significantly, the adsorbed phospholipids can also becollected very well.
Cartridge shape: S-type, L type
Functional groups: titanium dioxide, zirconium dioxide

TiO2
ZrO2

【Features】
Deproteinized and centrifugedsupernatantIntensity, cps• Phospholipids in the biological sample can beremoved in few easy steps.
• The matrix effect is reduced considerably since
it removes more than 90% of Phospholipids.
• Capable of processing small volume sample• Adsorbed phospholipids are easily recovered.

Sample clean up by MonoSpin Phospholipid( Removes more than 90% of phospholipids )Time （min）

Adsorption principle
The specific interaction of the metal oxide and phosphate compound retains the phospholipids in the packing material.
Hydrophilic

Hydrophobic

Phospholipids

Long-chain
fatty acids

Phosphate
functional
group

GlycerolBasic functional group(Ionic functional group)

Interaction

TiO2

ZrO2

MonolithCentrifuge

Operation

3,000 x g for 1 min

Sample Preparation
Mix 0.1 % formic acid and serum
sample 4:1 into 2mL micro tube.
↓
Use supernatant after centrifugation
at 10,000× g 30 sec

Centrifuge

Centrifuge

30 sec30 sec

1. Conditioning
0.1% formic acid in ACN:
200 μL

2. Apply

Phospholipid-free sample

Sample volume: 50 μL

Related Product
The FastRemover for Phospholipid 96-well plate delivers a fast and efficient removalof proteins and phospholipids in plasma and serum samples without sacrificing therecovery of your target analytes.

13

Publicly Available Reference
Functional group

C18

14

Compounds
Reference[1-(5-fluoropentyl)-1H-indol-3-yl](4-methyl-1Forensic Toxicol., 2013, 31(2), 333–337
naphthalenyl)methanone (MAM-2201)
α-Pyrrolidinovalerophenone
Forensic Toxicol., 2014, 32(1), 68–74
25-Hydroxyvitamin D3
Anal. Sci., 2018, 34(9), 1043-1047
Aconitines and Colchicine
Chromatographia, 2015, 78(15), 1041–1048
Amphetamines
J. Chromatogr. A, 2008, 1208(1-2), 71-75
Amphetamines
Anal. Chim. Acta, 2010, 661(1), 42-46
a-Pyrrolidinovalerophenone (a-PVP) and a-pyrrolidinobutiophenone
Forensic Toxicol., 2014, 32, 68-74(a-PBP)
DesaltingAmino Acids., 2018, 50(1), 117–124
DesaltingOrg. Biomol. Chem., 2018, 17(1), 165-171
Desalting
J. Proteomics, 2018, 181, 238-248
Desalting
J. Pept. Sci., 2018, 24(12), e3133
Desalting of LaIT1
Mass Spectrometry, 2017, 6(1), A0059
Desalting of LaIT1
J. Pept. Sci., 2015, 21(8), 636-643
Dibucaine、Naphazoline
J. Chromatogr. B, 2008, 872, (1-2), 186-190
Diquat, Paraquat
Anal. Bioanal. Chem., 2011, 400(1), 25–31
Diquat, Paraquat
Anal. Bioanal. Chem., 2011, 400(1), 25-31
Drugs
J. Chromatogr. B, 2008, 867(1), 99-104
Drugs
Chromatographia, 2009, 70(3), 519-526
Eperisone, Tolperisone
J.Health Sci., 2010, 56(5), 598-605
Eperisone, Tolperisone, and Tizanidine
J.AOAC Int. 2014, 97(6), 1546-1551
Flavonoid
J. Chem. Ecol. 2016, 42(12), 1226-1236
glucocorticoids
J. Chromatogr. B, 2017, 1057, 62-69
IodideAm. J. Mod. Chromatogr., 2015, 2(1), 1-6
iTRAQ labeled desalting
Int. J. Oncol., 2015, 47(1), 384-390
Liraglutide
J. Chromatogr. B, 2018, 109, 29-35
MAM-2201
Forensic Toxicology. 2013, 31(2), 333–337
Medicinal toxicants
J. Clin. Pharm. Ther., 2017, 42(4), 454-460
N-1-Naphthalenyl-1-pentyl-1H-indole-3-carboxamide
Forensic Toxicol., 2015, 33(1), 165–169
Nanoparticles
J. Chromatogr. A, 2015, 1404, 141-145
NaringinJ. Clin. Pharmacol., 2013, 53(7), 738-745
Organophosphorus compounds
Anal. Sci., 2011, 27(10), 999-1005
Oxidized phospholipids
J. Lipid. Res., 2017, 58(11), 2229-2237
oxPUFAs
Sci. Rep., 2018, 8, 7954
PeptidesCancer Res., 2017, 77(4), 926-936
PeptidesBio protocol. 2015, 5(8), 2015
PeptidesClin. Exp. Nephrol., 2018, 22(4), 782–788
PeptidesBiosci. Biotechnol. Biochem., 2017, 81(12), 2237-2243
PeptidesMethods Mol. Biol. 2018, 1696, 91-105
PeptidesBiosci. Biotechnol. Biochem., 2018, 82(8), 1309-1315
PeptidesData Brief., 2018, 31(17), 604-609
PeptidesData Brief., 2017, 12(11), 252-257
PeptidesBioresour. Technol., 2018, 254, 278-283
PeptidesBiomass Bioenergy, 2016, 91, 83-90
PeptidesNeurogenetics, 2019, 20(1), 9-25
PeptidesJ. Proteomics, 2015, 119, 183-195
PeptidesProc. Natl. Acad. Sci., 2018, 115(14), 3646-3651
PeptidesOncogene, 2017, 36(26), 3740-3748. doi: 10.1038/onc.2016.524
PeptidesSci. Rep., 2018, 22, 8(1), 1303
PeptidesSci. Rep., 2016, 6, 26723
PeptidesProteomics, 2013, 13(5), 751-755
PeptidesJ. Proteomics., 2013, 84(12), 40-51
Phthalate esters
J. Pharm. Anal., 2011, 1(2), 92-99
Phthalates
J. Pharm. Anal., 2011, 1(2), 92-99
Plant samples
Sci. Rep., 2017, 7(1), 1243. doi: 10.1038/s41598-017-01390-3
Purines
Nucleosides Nucleotides Nucleic Acids, 2018, 37(6), 348-352
Pyrrolidinophenone type designer
J. Chromatogr. B, 2013, 30, 942-943
Pyrrolidinophenone-type designer drugs
J. Chromatogr. B, 2013, 942-943, 15-20
review
Bioanalysis., 2015, 7(17), 2171-2176

Publicly Available Reference
Functional group
Compounds
C18 FF
Drugs
C18, C18CX
Cardiovascular drug
Melamine
C18, SCX
PeptidesC18, TiO
PeptidesC18, SAX
Aamphetamines, Opiates, and THC
C18-AX
Oxidized Fatty Acids
Arsenite, Arsenate, and Methylarsenate
Clean up
C18-CX
Drugs
Halogenated compounds
Amide
PA-labelled glycans
CBA
clenbuterol
CBA, Amide
Tetrodotoxin
nanoparticles
Oligosaccharides
NH2
PA labeled N-glycans
PA-labelled glycans
Pyridylaminated Oligosaccharides
Adenosine
Allergenic ingredients
Catecholamines
Catecholamines
Catecholamines
Catecholamines
PBA
Catecholamines
Catecholamines
Catecholamines
Cis-diol groups
hippocampal monoamines
Pyridylamino monosaccharide
Serotonine and Noradrenaline
Phospholipid
Farnesyl pyrophosphate
ProteinA, G
IgG
IgG
ProteinG
IgG
IgG
Alendronate
Deoxyribonucleoside
SAX
metabolite of 18 F-THK5351
Urinary excretion
Amino acid
Amino acid
Amino acid
Amino acid
SCX
Angiogenic peptide
Fluoresence derivatization
iTRAQ-labeled peptides
Methylated lysine
Morphine, Codeine, Dihydrocodeine
TiO
Glyphosate
Protein digestion
TrypsinProtein digestion
review
review
review
review
review

Reference
J. Chromatogr. A, 2017, 1517, 9-17
Acta Chromatographica, https://doi.org/10.1556/1326.2018.00493
J. Anal. Sci. Meth. Instrum., 2012, 2, 68-73
Sci. Rep., 2017, 7(1), 11137
Int. J. Mol. Sci., 2018, 19(9), 2655
Forensic Toxicol., 2013, 31(2), 312–321
Mod. Chem. Appl., 2015, 3, 3
J. Sep. Sci., 2012, 35(18), 2506-2513
J. Occup. Health., 2018, 60(2), 140-147
J. Sep. Sci., 2011, 34(16-17), 2232-2239
Toxicology, 2013, 314(1), 22-9
Bicsci. Biotechnol. Biochem., 2012, 76(10), 1982-1983
Talanta, 2018, 186, 521-526
Chromatographia, 2014, 77, (9-10), 687–693
J. Sep. Sci., 2015, 38, 283–290
Sci Rep. 2017, 26(7) :46099. doi
Glycoconj. J., 2017, 34(4), 537-544
Plant Biotechnol. J., 2016, 14(8), 1682-1694
Anal. Sci., 2016, 32(5), 487-490
Biosens. Bioelectron., 2013, 15(41), 379-385
Food Control, 2018, 84, 89-96
J. Comp. Neurol., 2016, 524(18), 3849-3864
Food Chem., 2019, 276, 376-382
EBioMedicine., 2016, 8, 60-71
PLoS One, 2018, 13(7), e0201203
J. Chromatogr. B, 2015, 985, 142-148
Biol. Pharm. Bull., 2017, 40(2), 227-233
Biosci. Biotechnol. Biochem., 2018, 82(3), 497-506
Anal. Chim. Acta., 2015, 857(1), 64-70
J. Pharmacol. Sci., 2016, 132(4), 249-254
Bicsci. Biotechnol. Biochem., 2011, 75(7), 1405-1407
Br. J. Pharmacol., 2015, 172(5), 1250-1262
Anal. Bioanal. Chem., 2017, 409(14), 3551–3560
Biochimie., 2018, 145, 113-124
Virology, 2019, 15, 527, 132-140
PLoS One, 2017, 12(7):e0181181
Bioanalysis, 2018, 10(18), 1501-1510
Legal. Medicine, 2018, 30, 14-20
Biotechnol., 2016, 228, 52-57.
Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(12), 2211-2218
Nucleosides Nucleotides Nucleic Acids. 2016, 35(10-12), 559-565.
Psychiatry Res., 2016, 238, 203-210
J. Sep. Sci., 2014, 37(16), 2087-2094
Sci. Rep., 2018, 8(1), 14587
Orig. Life Evol. Biosph., 2013, 43(2), 99-108
BioSci. Trends, 2016, 10(6), 500-506
Biomed. Chromatogr., 2012, 26(2), 147-151
Biochim. Biophys. Acta, 2018, 1865(6), 874-888
Anal. Bioanal. Chem., 2018, 410(17), 4189–4194
J. AOAC Int., 2011, 94(3), 765-774.
Acta Chromatographica, https://doi.org/10.1556/1326.2018.00513
J. Am. Chem. Soc., 2018, 140(38), 11982-11991
Anal. Sci., 2018, 34(4), 397-406
Forensic Toxicol., 2010, 28(2), 61–68
Trac. Trends Anal. Chem., 2013, 45, 182-196
Electrophoresis. 2017, 38(22-23), 2851-2869
Chromatogr., 2015, 2(1), 79-95
J. Pharm. Biomed. Anal., 2018, 161, 51-60

15

MonoSpin ProA, MonoSpin ProG

MonoSpin ProA and MonoSpin ProG are already immobilized
onto a silica monolith offering rapid purification of antibodies.
Additionally, a 96-well plate format is available to purify amulti-analyte. Each reagent for the purification of samples isattached.

【Features】
The silica is modified with a hydrophilic polymer and then immobilized with either Protein A or Protein G to prevent theadsorption of proteins, resulting in higher purification and recovery of antibodies.

【Specification】
ProteinA

Hydrophilic polymer

Silica monolith surfaces immobilized with Protein A andProtein G have modified hydrophilic polymers,
suppressing the non-specific adsorption of proteins andallowing the recovery of purer antibodies.

Through-pore size

： 2 µmMeso-pore size

： 60 nm

Disk size： 4.2 ×1.5 mm

Sample Volume： 500 μL

Sample Volume： 50 μL

Centrifugation speed： 2,300 ×g＊

Recovery rates： 400 μg （IgG）*:96-well plate type can also be used with vacuum aspiration (e.g., −0.015 MPa).

ShapesSpin Column Type96 Well plate type

• Purification with compact tabletop centrifuge just in
two minutes (e.g., 2,300 × g)
• Appropriate for purification of small volume sample(approximately 0.4 mg)• Purification by both aspiration or centrifuge• Available for a multi-analyte with the same spincolumn volume.

Large Spin Column

・Maximum 16 mg antibody can be recovered bycentrifuge.

16

MonoSpin ProA, MonoSpin ProG
Ultra-high-speed processing ensures stable recovery
Antibodies can be easily purified by centrifugation in a short time in a tabletop centrifuge With silica monoliths.
When collecting antibodies, the neutralizing solution can be added to the collection tube in advance to immediately
neutralize the antibodies collected by the acid immediately. This action greatly reduces the risk of antibody
degeneration.

Centrifuge

Centrifuge

Centrifuge

Centrifuge

30 sec30 sec30 sec30 sec

1. Conditioning

2. Adsorption

3. Wash

4. Elution

Purified sample
Centrifuge : 2,300 ×g

As shown below, the antibody concentrations were determined quantitatively from the medium of CHOcells. The
purified antibodies show very few impurities by the results of electrophoresis.
Calibration curve of IgG concentration

Results of recovery electrophorensis

抗体回収量
added (mg)of antibody ｍｇ
Amount0.6

1 2 3 4 5 6

回収したポリクローナル
Recovery of IgG
ヒトＩｇＧ抗体0.5

1. Marker

97.4 kDa
66.2 kDa

0.4

2. Medium45.0 kDa

3. Flow Through

0.3

4. Washing

31.0 kDa

0.2

5. Elution
21.5 kDa

0.1

6. Regeneration

14.4 kDa

0
0

0.2

0.4

0.6

Right page (mg)
抗体添加量
mg

Enrichment of Antibody Solution Using MonoSpin ProA
Human IgG solution (500 μL of 0.025 mg/mL) was applied to a MonoSpin ProG spin column 10 times (In = I1–I10).
Then, the elution of IgG concentration was determined twice with 100 μL elution buffer (En = E1 and E2). The first
IgG elution (E1) was 50 fold concentration of the standard solution and indicates a 90% recovery of IgG without
loss.

50 fold enrichment efficiency

Original
Sample

1

2

3

4

5

6

7

8

9

10

Wash

E=1

E=2

E=Elution17

MonoSpin ProA, MonoSpin ProG
Elution Volume and Recovery Rate Comparing with Other Brands Products
MonoSpin ProA needs only 100 µL elution buffer to obtain a recovery rate of at least 90% IgG. However,other brands' products require 400 µL or more elution buffer with a recovery rate of 70% IgG.

Elution Volume (μL)
400 μL

MonoSpin ProA

200 μL

90 % recovery rate of IgG with
100 μL100 μL elution.

400 μL

Brand T’s Product60 – 65 % recovery rate of IgG with

200 μL400 μL elution

100 μL※No elution of IgG

400 μL

Brand G’s Product200 μL

65 – 70 % recovery rate of IgG with
400 μL elution

100 μL

Recovery Rate (%)

Removal of preservatives in antibody solutions
IgG+Gelatin

IgG+BSA
0.10

ﾁｬﾝﾈﾙ A -- SPD-20A
ﾁｬﾝﾈﾙ A -- SPD-20A
2

0.10

ﾁｬﾝﾈﾙ A -- ﾁｬﾝﾈﾙ
SPD-20A
A -- SPD-20A

Before pretreatment

Before pretreatment

0.04

0.04

0.08

0.08

After pretreatment

After pretreatment

2 1

0.04

1 ： IgG
2 ： Gelatin
3 ： Elution Buffer

0.02

0.04

3

0.02

0.02

Volts

Volts

1

3

0.06

1 ： IgG
2 ： BSA3 ： Elution Buffer

Volts

Volts

0.06

0.02

0.00

0.00

0.00

0.00
0

2

4

6

8

10

Time(min)

12

14

16

18

20

0

2

4

6

8
10 12
Time(min)

14

16

18

20

MonoSpin ProA/ProG enables you to remove proteins such as BSA and Gelatin in antibody solutions without dilution.

18

MonoSpin ProA, MonoSpin ProG

Abs

Recovery of antibodies from CHO cell culture medium (96-well plate)

Well No.

Sample volume : 150 µL
Elution volume : 150 µL
Recovery rate : 90% (CV 3.1 %)IgG concentration : 1.3 mg/mL

Purification of multiple antibodies using MonoSpin L and ProA
Procedure
1. Apply 5 mL of equilibration buffer.

2. Apply sample (Max. 8 mL) after filtration through 0.2 µL filtration.

3. Apply 5 mL of washing buffer.

4. Apply 5 mL of elution buffer.
Centrifugal force at each step : 1,500 x g, 2 min* MonoSpin ProA/G buffer kit was used.

19

MonoSpin 96 Well Plate
MonoSpin 96WP is a multi-specimen pretreatment plate with immobilized silica monolith disks.
The same monolithic disks earlier used in MonoSpin have been fixed and designed to specifications that facilitate
the same amount of load and results as when spin columns are used.

MonoSpin

MonoSpin 96WP

Silica monolith gel【Features】
•
•
•
•
•

Fix the same gels as MonoSpin spin columns to a 96-well plate
Can be used with centrifugal or suction (−0.05 MPa or higher recommended)
Rapid pretreatment of biological samples is possible
Capable of processing solution compositions similar to spin columns
Extensive lineup【Application】• Purification of glycans• Recovery of drugs from biological samples (urine, serum,plasma)• Purification of catecholamines• Recovery and purification of organic acids• Desalting, purification, and fractionation of peptide
samples• Protein recovery and purification• Purification after iTRAQ derivatization

20

Description

Qty.

Cat.No.

MonoSpin 96WP C1815010-21900

MonoSpin 96WP NH2

15010-21901

MonoSpin 96WP PBA

15010-21902

MonoSpin 96WP SAX

15010-21903

MonoSpin 96WP SCX

15010-21904

MonoSpin 96WP Amide

1

5010-21905

MonoSpin 96WP CBA

1

5010-21906

MonoSpin 96WP C18-CX

1

5010-21907

MonoSpin 96WP C18-AX

15010-21908

96 Deep Well Plate / GL Sticker for 96 well plate
96 Deep Well Plate【Features】• Plate dimensions conform to SBS standards for the automatic operation ofdispensing machines• V-bottom well geometry reduces sample loss
• Made of polypropylene with outstanding heat, cold, and solvent resistance• Low adsorption (LB type) suppresses non-specific adsorption of proteins andpeptides by super hydrophilic surface treatment

Description

Material

Qty.

Cat.No.

MS Plate

Polypropylene

506045-00201

MS Plate
Low adsorption(LB type)

Polypropylene(hydrophobic polymer)

156045-00203

GL Sticker for 96 well plate
Evapo Less Slit

Sealing Sticker
Enlarged view

Enlarged view

【Features】【Features】• Sticker closes automatically after each application.
• Adhesive-free on top of the sticker to prevent
contamination.
• Can be operated under −80℃–100℃• High durability against organic solvent• High air leakage efficiency• Used to store samples down to −80℃

Description

Material

Qty.

Cat.No.

Evapo Less Slit

PET, Silicon

1005010-21950

Sealing Sticker

Polyolefin

1005010-21951

21Order Information
MonoSpin type S
Description
MonoSpin C18
MonoSpin C18 FF
MonoSpin Ph
MonoSpin C18-AX
MonoSpin C18-CX
MonoSpin SAX
MonoSpin SCX
MonoSpin NH2
MonoSpin CBA
MonoSpin Amide
MonoSpin PBA
MonoSpin TiO
MonoSpin Trypsin HP [ KEEP COOL ]MonoSpin ME
MonoSpin Phospholipid

Qty.
50
100
50
100
50
100
50
100
50
100
50
100
50
100
50
100
50
100
50
100
50
100
50
100
30
50
100
50
100

Cat.No.
5010-21700
5010-21701
5010-21670
5010-21671
5010-21733
5010-21734
5010-21735
5010-21736
5010-21731
5010-21732
5010-21720
5010-21721
5010-21725
5010-21726
5010-21710
5010-21711
5010-21729
5010-21730
5010-21727
5010-21728
5010-21715
5010-21716
5010-21705
5010-21706
7510-11302
5010-21737
5010-21738
5010-21698
5010-21699

MonoSpin Type S

Recovery tube
(1.7 mL)

MonoSpin type S Trial kit
Trial and custom kits are shipped with various columns packaged for initial method development.
Description
MonoSpin Trial Kit 1
MonoSpin Trial Kit 2
MonoSpin Trial Kit 3

22

Content
C18, TiO, SCX, SAX 10 eachC18, Amide, CBA, NH2 10 each
SCX, SAX, CBA, NH2 10 each

Cat.No.
5010-21740
5010-21741
5010-21742

Liquid waste tube
(2 mL)

MonoSpin type L
Description

Qty.
30
30
30
30
30
30
30

MonoSpin L C18
MonoSpin L SAX
MonoSpin L SCX
MonoSpin L NH2
MonoSpin L CBA
MonoSpin L ME
MonoSpin L Phospholipid

Cat.No.
7510-11320
7510-11321
7510-11322
7510-11323
7510-11324
7510-11325
7510-11326

MonoSpin type L

MonoSpin 96 well plate
Description
MonoSpin 96WP C18
MonoSpin 96WP NH2MonoSpin 96WP PBA
MonoSpin 96WP SAX
MonoSpin 96WP SCX
MonoSpin 96WP Amide
MonoSpin 96WP CBA
MonoSpin 96WP C18-CX
MonoSpin 96WP C18-AX

Qty.
1
1
1
1
1
1
1
1
1

Cat.No.
5010-21900
5010-21901
5010-21902
5010-21903
5010-21904
5010-21905
5010-21906
5010-21907
5010-21908

Qty.
10
10
1
1
4
4
−

Cat.No.
7510-11310
7510-11311
7510-11312
7510-11313
7510-11314
7510-11315
7510-11316

MonoSpin ProA, MonoSpin ProG
Description
MonoSpin ProA column
MonoSpin ProG column
MonoSpin ProA 96 well plate
MonoSpin ProG 96 well plate
MonoSpin L ProA
MonoSpin L ProG
MonoSpin ProA/G buffer kit[ KEEP COOL ][ KEEP COOL ][ KEEP COOL ][ KEEP COOL ][ KEEP COOL ][ KEEP COOL ][ KEEP COOL ]23

GL Sciences disclaims any and all responsibility for any injury or damage which may be caused by this data directly or indirectly.
We reserve the right to amend this information or data at any time and without any prior announcement. Please note that , in the interests of continuous improvement, models or
specifications are subject to change without notice. Please also note that the company name and product name appearing in this catalogue are the trademark or registeredtrademark of each corresponding company. In the descriptions in this catalogue, TM and R marks are not used.

GL Sciences Inc. JapanGL Sciences Inc. USA

GL Sciences B.V.

GL Sciences (Shanghai)22-1 Nishishinjuku 6-chome
Shinjuku-ku, Tokyo
163-1130, Japan

4733 Torrance Blvd. Suite 255
Torrance, CA 90503
USA

Dillenburgstraat 7C
5652AM, Eindhoven
The Netherlands

Phone: +81-3-5323-6620
Fax: +81-3-5323-6621
Email: world@gls.co.jp
Web: www.glsciences.com

Phone: +1-310-265-4424
Fax: +1-310-265-4425
Email: info@glsciencesinc.com
Web: www.glsciencesinc.com

Phone: +31-40-254-9531
Email: info@glsciences.eu
Web: www.glsciences.eu

Limited Tower B, Room 2003
Far East International Plaza
No. 317 Xianxia Road, Changning District
Shanghai, China 200051

International Distributors
Visit our Website at www.glsciences.com/distributors

Phone: +86-21-6278227
Email: contact@glsciences.com.cn
Web: www.glsciences.com.cn

Published in Japan, July 29, 2022(PDF)
EN1074-20220729PDF